The Role of Vincristine in Myelomatosis Treatment
Author Information
Author(s): I.C.M. MacLennan, J. Cusick
Primary Institution: University of Birmingham Medical School
Hypothesis
Does adding vincristine to first line treatment improve survival in myelomatosis patients?
Conclusion
The addition of vincristine to first line treatment did not improve survival in myelomatosis patients.
Supporting Evidence
- 530 patients were analyzed in the trial.
- Survival was not improved by the addition of vincristine.
- Patients reaching plateau phase had a slight survival advantage when not receiving further treatment.
Takeaway
Doctors wanted to see if vincristine helps people with a type of blood cancer called myelomatosis, but it didn't make them live longer.
Methodology
530 patients were randomly assigned to receive either melphalan and prednisone alone or with vincristine, and their survival was tracked.
Limitations
The study did not find significant survival benefits, and the follow-up time may not be sufficient to draw final conclusions.
Participant Demographics
Patients were previously untreated and below 75 years of age.
Statistical Information
Statistical Significance
p>0.5
Want to read the original?
Access the complete publication on the publisher's website